Trinity News and Events
25th February 2021
Back in March 2020, the Health Research Board (HRB) in cooperation with the Irish Research Council (IRC) launched the
COVID-19 Rapid Response Call to fund research to provide evidence for the national and global efforts to deal with the virus outbreak. The funding process was a highly competitive one and several awards were received by Trinity investigators.
One such project, led by
Professor Orla Hardiman, from
the Academic Unit of Neurology at the School of Medicine was to provide virtual support for patients with Motor Neuron Disease (MND).
Professor Hardiman and her clinical and research team at Beaumont Hospital and Trinity College Dublin launched a rapid response to manage MND (Motor Neurone Disease) during the COVID-19 pandemic. The need for remote monitoring and delivery of highly specialised care, away from a hospital setting, became vital to protect vulnerable MND patients when Covid-19 hit. Using their collaborator Sheff
NeuroSense Therapeutics Receives European Orphan Drug Designation for ALS Drug
USA - English
News provided by
Share this article
HERZLIYA, Israel, Jan. 12, 2021 /PRNewswire/
NeuroSense Therapeutics, a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Their treatment for Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming at slowing or halting the disease progression, has received orphan designation from the EMA (European Medicines Agency) for their first candidate, PrimeC. This decision from the EMA complements an earlier orphan designation which was granted in 2020 by the American Food and Drug Administration. Together, these designations grant PrimeC seven and ten years of market exclusivity in the US and European Union, respectively
Top story: Silencing of an ALS gene safely delivered to patients in UMass Medical School study
Synthetic microRNA treatment targets mutant SOD1 gene that causes ALS By Jim Fessenden December 24, 2020
As this unprecedented year comes to a close, the Office of Communications is rerunning some of the big stories of 2020 that highlight the incredible work of the UMass Medical School community. From the first-in-the-nation early graduation of our medical students to the essential clinical research that lead to a SARS-CoV-2 vaccine, from the tremendous growth of the institution’s research funding to ground broken on the new research and education building, we have so much to be proud of. Look for these stories on UMassMed News